Cancer authority pulls together the principles, practice and ethics of cancer care

January 04, 2017

Samuel Hellman, MD, the former Dean of the Division of Biological Sciences and the Pritzker School of Medicine at the University of Chicago, "cannot remember a time when I did not want to become a doctor."

The field of cancer research is glad he felt that calling. Many patients worldwide have benefitted from innovations during his distinguished career in cancer care, research, teaching and administration. The short list of his career highlights includes roles as co-editor of seven editions of the world's leading cancer textbook, former physician-in-chief at the nation's top cancer center, former chairman of radiation therapy at the Harvard Medical School and past president of two of the country's most influential cancer organizations.

Graduating from Allegheny College and SUNY Upstate Medical College, he received postgraduate training at Harvard and Yale, and a fellowship at London's Royal Marsden Hospital. Along the way, he published scores of academic manuscripts, editorials, essays, opinion pieces and reminiscences in an array of high-impact medical journals as well as more general magazines.

Selected publications that are accessible to a general audience, plus a few unpublished pieces, have now been compiled into a book, Learning While Caring: Reflections on a Half-Century of Cancer Practice, Research, Education and Ethics, published in January 2017 by Oxford University Press.

The title, Learning While Caring, is instructive. Physicians have no choice but to continue their professional education while practicing medicine, Hellman argues. "Lifelong learning is essential," he insists, but keeping up with the literature and presenting at meetings must be combined with skills learned more informally through the experience of caring for patients. Much of what is taught in medical school needs to be revised or modified or even discarded throughout the physician's career. "Medicine is a learned profession," he wrote, "but perhaps more important, it is a learning profession."

The book includes three dozen essays and commentaries, presented in five sections - medical ethics and learning, academic medicine, research, perceptions of cancer, and heroes - with each section organized chronologically.

The section on ethics, the longest, focuses on the author's "uneasiness" with the process of randomized clinical trials. In such trials, the immediate interests of a patient may compete with the long-term benefits to society, placing the physician in a position that Hellman describes as "ethically intolerable."

It is a doctor's primary responsibility, Hellman insists, to "act as a patient's agent." This "takes precedence over his responsibility as a scientist."

He also argues that medicine should not be intellectually or physically separate from other academic activities in the university. Patient care draws as much from the humanities and social sciences as from the biological and physical sciences. And a good general education must include some medically related science. "You can't consider genetic engineering of plants or animals, including humans," he insists, "without understanding what a gene is and how it functions."

The section on academic medicine features a humorous interlude, "Tales of the Unnatural," published in JAMA shortly after Halloween in 1998. This essay, should be required reading for up and coming physician-scientists considering leadership roles.

Hellman sets the tone by pointing out that altering just one letter converts the title of dean into dead - a transformation that suggests how the office holder is subsequently perceived by former friends and colleagues. He next describes the hierarchy of the academic nobility. Department chairs and senior faculty, for example are vampires of available resources. Lower ranking faculty, administrators, board members and even donors are all endowed with comparably ghoulish titles.

Although a few of the selections in the section on research contain some scientific or medical jargon, they remain quite readable. Much of this section focuses on the gradual, grudging evolution of breast cancer treatment. Hellman was among the early advocates for replacing radical mastectomies in patients with early-stage disease with much less disfiguring operations - limited tumor removal followed by radiation therapy. Over time, this became the preferred approach.

As part of this crusade, Hellman and his Harvard and University Chicago colleague, Ralph Weichselbaum, coined the term "oligometastasis," referring to an intermediate spectrum of states between confined and widespread disease. Controversial at first, oligometastasis is now generally accepted and has considerable therapeutic importance.

The next section is concerned with the perception of cancer by the general public, the patient and even the different medical specialties and providers. This is affected by is its metaphoric use in western culture. In order for cancer to be properly considered, Hellman stresses, it must be demythologized.

The book ends with Hellman's carefully considered thoughts about two of his medical heroes: Thomas Hodgkin, for whom Hodgkin's disease was named and a model for the scholarly physician; and Marie Curie, who won the Nobel Prize twice, for the discovery of radium, essential for early radiation therapy, and its chemistry. Both were chosen not only for their scientific distinction but also for their involvement in the important affairs of their time.

In a closing summary, Hellman shares some pithy advice, acquired during a 50-year revolution in biology and medicine that brought practical, philosophical, and societal issues with which academia, medicine and cancer care continue to grapple:
-end-


University of Chicago Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.